Ahmet Murat Aydin, MD

Research Program: Cancer Therapeutics Faculty Rank: Assistant Professor Campus: University of Arkansas for Medical Sciences College: College of Medicine Department: Urology

Cancer Research Interest

• Disease Site Focus: GU
• Research Focus Area: Treatment, Health Disparities, Carcinogenesis, Diagnosis/ Prognosis, Prevention
• Type of Research: Translational, Clinical
• Research Keywords: Cancer Immunotherapy, Biomarker, Health Outcomes
• Research Interest Statement: My main research focus is characterization of immune suppressive mechanisms in genitourinary tumors, and development of novel dendritic cell-based cancer vaccines and T-cell based therapies against non-metastatic kidney and bladder cancers.

Contact Information

• Email Address: MAYDIN@UAMS.EDU
• Profiles Research Networking Software: View Profile

Open Clinical Trials

• “A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Scheduled for Radical Cystectomy and Are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy” (NCT04919512)
• “EA8192 A Phase II/III Trial of MED14736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy” (NCT04628767)

Publications

• Aydin AM, Cheriyan SK, Reich R, [et al.]. Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer. Urologic oncology. 2022. PMID: 35811208.
• Aydin AM, Reich RR, Cao B, [et al.]. Clinical indications for necessary and discretionary hospital readmissions after radical cystectomy. Urologic oncology. 2021. PMID: 34629281. PMCID: PMC8960322.
• Chakiryan NH, Kimmel GJ, Kim Y, [et al., including Aydin AM]. Geospatial Cellular Distribution of Cancer-Associated Fibroblasts Significantly Impacts Clinical Outcomes in Metastatic Clear Cell Renal Cell Carcinoma. Cancers. 2021 13(15). PMID: 34359645. PMCID: PMC8345222.
• Hajiran A, Azizi M, Aydin AM, [et al.]. Retroperitoneal Lymph Node Dissection Versus Surveillance for Adult Early Stage Pure Testicular Teratoma: A Nationwide Analysis. Annals of surgical oncology. 2021 28(7):3648-3655. PMID: 33689081. PMCID: PMC9801512.
• Chakiryan NH, Hajiran A, Kim Y, [et al., including Aydin AM]. Correlating Immune Cell Infiltration Patterns with Recurrent Somatic Mutations in Advanced Clear Cell Renal Cell Carcinoma. European urology focus. 2021. PMID: 33994165.
• Aydin AM, Hall M, Bunch BL, [et al.]. Expansion of tumor-infiltrating lymphocytes (TIL) from penile cancer patients. International immunopharmacology. 2021 94:107481. PMID: 33636562. PMCID: PMC8205103.
• Hajiran A, Chakiryan N, Aydin AM, [et al.]. Reconnaissance of tumor immune microenvironment spatial heterogeneity in metastatic renal cell carcinoma and correlation with immunotherapy response. Clinical and experimental immunology. 2021 204(1):96-106. PMID: 33346915. PMCID: PMC7944355.
• Aydin AM, Bunch BL, Beatty M, [et al.]. The Factors Affecting Expansion of Reactive Tumor Infiltrating Lymphocytes (TIL) From Bladder Cancer and Potential Therapeutic Applications. Frontiers in immunology. 2021 12:628063. PMID: 33717150. PMCID: PMC7949015.
• Hajiran A, Azizi M, Aydin AM, [et al.]. Reply By Authors. The Journal of urology. 2021 205(1):108. PMID: 33095102.
• Hajiran A, Zemp L, Aydin AM, [et al.]. Topical chemotherapy for penile carcinoma in situ: Contemporary outcomes and reported toxicity. Urologic oncology. 2021 39(1):72.e1-72.e5. PMID: 33036902.
• Hajiran A, Azizi M, Aydin AM, [et al.]. Pathological and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed by Cystectomy with or without Neoadjuvant Chemotherapy. The Journal of urology. 2021 205(1):100-108. PMID: 32783489. PMCID: PMC7864376.
• Chakiryan NH, Kimmel GJ, Kim Y, [et al., including Aydin AM]. Spatial clustering of CD68+ tumor associated macrophages with tumor cells is associated with worse overall survival in metastatic clear cell renal cell carcinoma. PloS one. 2021 16(4):e0245415. PMID: 33882057. PMCID: PMC8059840.
• Bunch BL, Morse J, Asby S, [et al., including Aydin AM]. Systemic and intravesical adoptive cell therapy of tumor-reactive T cells can decrease bladder tumor growth in vivo. Journal for immunotherapy of cancer. 2020 8(2). PMID: 33303579. PMCID: PMC7733200.
• Aydin AM, Chakiryan NH, Spiess PE. Will Dynamic Sentinel Lymph Node Biopsy Become the New International Standard for Evaluating High-risk Penile Cancer in Patients with Clinically Negative Lymph Nodes?. European urology. 2020 78(6):873-874. PMID: 33023773.
• Chertack N, Ghandour RA, Singla N, [et al., including Aydin AM]. Overcoming sociodemographic factors in the care of patients with testicular cancer at a safety net hospital. Cancer. 2020 126(19):4362-4370. PMID: 32776520.
• Aydin AM, Chahoud J, Adashek JJ, [et al.]. Understanding genomics and the immune environment of penile cancer to improve therapy. Nature reviews. Urology. 2020 17(10):555-570. PMID: 32812000.
• Aydin AM, Gage K, Dhillon J, [et al.]. Focal bipolar radiofrequency ablation for localized prostate cancer: Safety and feasibility. International journal of urology : official journal of the Japanese Urological Association. 2020 27(10):882-889. PMID: 32767444.
• Aydin AM, Baydar DE, Hazir B, [et al.]. Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy. World journal of urology. 2020 38(10):2537-2545. PMID: 31900581.
• Azizi M, Aydin AM, Hajiran A, [et al.]. Systematic Review and Meta-Analysis-Is there a Benefit in Using Neoadjuvant Systemic Chemotherapy for Locally Advanced Penile Squamous Cell Carcinoma?. The Journal of urology. 2020 203(6):1147-1155. PMID: 31928407.
• Azizi M, Aydin AM, Hajiran A, [et al.]. Reply by Authors. The Journal of urology. 2020 203(6):1155. PMID: 32176595.
• Cheriyan SK, Nicholson M, Aydin AM, [et al.]. Current management and management controversies in early- and intermediate-stage of nonseminoma germ cell tumors. Translational andrology and urology. 2020 9(Suppl 1):S45-S55. PMID: 32055485. PMCID: PMC6995850.
• Azizi M, Aydin AM, Cheriyan SK, [et al.]. Therapeutic strategies for uncommon testis cancer histologies: teratoma with malignant transformation and malignant testicular sex cord stromal tumors. Translational andrology and urology. 2020 9(Suppl 1):S91-S103. PMID: 32055490. PMCID: PMC6995843.
• Aydin AM, Zemp L, Cheriyan SK, [et al.]. Contemporary management of early stage testicular seminoma. Translational andrology and urology. 2020 9(Suppl 1):S36-S44. PMID: 32055484. PMCID: PMC6995845.
• Aydin AM, Singla N, Panwar V, [et al.]. Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study. World journal of urology. 2019 37(11):2419-2427. PMID: 30759271.
• Hajiran A, Aydin AM, Cheriyan SK, Sexton WJ. A simplified new-generation renal mass complexity scoring system. Annals of translational medicine. 2019 7(Suppl 6):S223. PMID: 31656802. PMCID: PMC6789356.
• Aydin AM, Cheriyan S, Spiess PE. Treating advanced penile cancer: where do we stand in 2019?. Current opinion in supportive and palliative care. 2019 13(3):249-254. PMID: 31082941.
• Aydin AM, Pow-Sang JM. Editorial Comment. The Journal of urology. 2019 201(6):1125-1126. PMID: 30864907.
• Aydin AM, Haberal B, Artykov M, [et al.]. Clinicopathological predictors of positive 68Ga-PSMA-11 PET/CT in PSA-only recurrence of localized prostate cancer following definitive therapy. Annals of nuclear medicine. 2019 33(5):326-332. PMID: 30778860.
• Ceyhan E, Ileri F, Ceylan T, [et al., including Aydin AM]. Predictors of Recurrence and Complications in Pediatric Pyeloplasty. Urology. 2019 126:187-191. PMID: 30682463.
• Woldu SL, Moore JA, Ci B, [et al., including Aydin AM]. Practice Patterns and Impact of Postchemotherapy Retroperitoneal Lymph Node Dissection on Testicular Cancer Outcomes. European urology oncology. 2018 1(3):242-251. PMID: 31058267. PMCID: PMC6494089.
• Singla N, Krabbe LM, Aydin AM, [et al.]. Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma. Urologic oncology. 2018 36(7):343.e1-343.e8. PMID: 29748098.
• Tonyali S, Aydin AM. Evaluation of Deceased Kidney Donors for Renal Stone Disease: Is Computed Tomography Needed?. Current urology. 2018 11(3):113-116. PMID: 29692689. PMCID: PMC5903464.
• Woldu SL, Aydin AM, Rao AV, [et al.]. Differences at Presentation and Treatment of Testicular Cancer in Hispanic Men: Institutional and National Hospital-based Analyses. Urology. 2018 112:103-111. PMID: 29079210.
• Boegemann M, Aydin AM, Bagrodia A, Krabbe LM. Prospects and progress of immunotherapy for bladder cancer. Expert opinion on biological therapy. 2017 17(11):1417-1431. PMID: 28832261.
• Aydin AM, Katipoglu K, Baydar DE, Bilen CY. Long-standing aggressive angiomyxoma as a paratesticular mass: A case report and review of literature. SAGE open medical case reports. 2017 5:2050313X17712090. PMID: 28616233. PMCID: PMC5459349.
• Aydin AM, Woldu SL, Hutchinson RC, [et al.]. Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer. OncoTargets and therapy. 2017 10:1487-1502. PMID: 28331342. PMCID: PMC5352238.
• Aydin AM, Eldem G, Peynircioglu B, [et al.]. Local recurrence of renal cell carcinoma that simulated multiple renal arteriovenous fistulas after laparoscopic partial nephrectomy: Report of a rare case. International journal of urology : official journal of the Japanese Urological Association. 2016 23(10):888-891. PMID: 27416885.